The story of Sildenafil presents a complex case for stakeholders in the medicinal sector. While initially a blockbuster success, generating vast sums, the exclusivity lapse and the subsequent entry of off-brand versions have significantly impacted revenue. This raises questions about the long-term sustainability of similar therapeutic projects and